Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: a cross-sectional study
Abstract
Introduction: There is no clear relationship between type 2 diabetes mellitus and lung function decline; it is also unclear whether the type of treatment can modify spirometric variables and levels of inflammatory biomarkers. Objectives: To compare pulmonary function in patients with type 2 diabetes treated with an insulin-sensitizing agent (metformin) and in those treated with secretagogues, as well as combined with insulin, and to evaluate differences in inflammatory biomarkers between treatment groups. Material and methods: We conducted a cross-sectional analytic study in 196 diabetic patients with type 2 diabetic mellitus. Spirometric variables and levels of inflammatory biomarkers (ferritin, fibrinogen, C-reactive protein, interleukin 6, tumor necrosis factor-alpha), were obtained. Residual values (observed minus expected) for forced vital capacity and for forced expiratory volume were calculated and compared between treatment types. Differences in median levels of biomarkers were also compared. Results: After adjustment by known determinants of lung function, and by the control and duration of type 2 diabetes, patients treated with the insulin-sensitizing agent had statistically significant lower differences against expected values for forced vital capacity compared with secretagogues (-212.1 ml vs 270.2 ml, p=0.039), as well as for forced expiratory volume, but without statistical significance (-133.2 mL vs -174.8 mL, p>0.05). In the group of patients treated with the insulin-sensitizing agent, ferritin and tumor necrosis factor-alpha levels were lower (p<0.01). Conclusion: This study supports the hypothesis that insulin-sensitizing agents appear to be associated with less deterioration of lung function and less systemic inflammation in type 2 diabetes. The present study serves to formulate new hypothesis and research projects.
Downloads
References
Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9. http://dx.doi.org/10.1016/S0140-6736(08)61113-7
Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, et al . Effective therapy has altered the spectrum of cause specific mortality following HIV seroconversion. AIDS. 2006;20:741-9. http://dx.doi.org/10.1097/01.aids.0000216375.99560.a2
Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML , et al . Epidemiology of human immunodeficiency virus associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Supl.1):S5-14. http://dx.doi.org/10.1086/313843
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. http://dx.doi.org/10.1056/NEJMra041811
Núñez M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. J Hepatol. 2006;44:S132-9. http://dx.doi.org/10.1016/j.jhep.2005.11.027
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al . Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00025
Low-Beer S, Yip B, O´Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Synd. 2000;23:360-1.
Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Inter J Infect Dis. 2009;13:552-9. http://dx.doi.org/10.1016/j.ijid.2008.10.008
Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT , et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Synd. 2006;43:27-34. http://dx.doi.org/10.1097/01.qai.0000233310.90484.16
D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet. 2008;371:1417-26. http://dx.doi.org/10.1016/S0140-6736(08)60423-7
British HIV Association. Standards for HIV clinical care. London: BHIVA; 2007.
Ministerio de la Protección Social. Resolución número 3442 de 2006. Por la cual se adoptan las Guías de Práctica Clínica Basada en Evidencia para la prevención, diagnóstico y tratamiento de pacientes con VIH/sida y enfermedad renal crónica y las recomendaciones de los modelos de gestión programática en VIH/sida y de prevención y control de la enfermedad renal crónica. Bogotá: Ministerio de la Protección Social; 2006.
Ministerio de Protección Social , Fundación para la Investigación y Desarrollo de Salud y la Seguridad Social (FEDESALUD), Programa de Apoyo a la Reforma de Salud - PARS. Modelo de gestión programática en VIH/sida. Bogotá: Ministerio de la Protección Social; 2006.
Mugavero MJ, Dávila JA, Nevin CR, Giordano TP. From access to engagement: Measuring retention in outpatient HIV clinical care. AIDS Patient Care STDS. 2010;24:607-13. http://dx.doi.org/10.1089/apc.2010.0086
Weigel R, Hochgesang M, Brinkhof MW, Hosseinipour MC, Boxshall M, Mhango E, et al . Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis. 2011;11:31. http://dx.doi.org/10.1186/1471-2334-11-31
Brinkhof MW, Pujades-Rodríguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: Systematic review and meta-analysis. PLoS One. 2009;4:e5790. http://dx.doi.org/10.1371/journal.pone.0005790
Gardner EM, McLees MP, Steiner JF, Del Río C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793-800. http://dx.doi.org/10.1093/cid/ciq243
Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al . Loss to follow-up in an international, multicentre observational study. HIV Med. 2008;9:261-9. http://dx.doi.org/10.1111/j.1468-1293.2008.00557.x
Krishnan S, Wu K, Smurzynski M, Bosch RJ, Benson CA, Collier AC, et al . Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: An AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clin Trials. 2011;12:190-200. http://dx.doi.org/10.1310/HCT1204-190
Elenga N, Georger-Sow MT, Messiaen T, Lamaury I, Favre I, Mathieu Nacher, et al . Incidence and risk factors for follow-up interruption of HIV infected patients in Guadeloupe. J Aids Clin Res. 2013:4:238. http://dx.doi.org/10.4172/2155-6113.1000238
Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K, Siika AM, et al . Influence of gender on loss to follow-up in a large HIV treatment programme in Western Kenya. Bull World Health Organ. 2010;88:681-8. http://dx.doi.org/10.2471/BLT.09.064329
Zhou J, Tanuma J, Chaiwarith R, Lee CK, Law MG, Kumarasamy N, et al . Loss to follow-up in HIV-infected patients from Asia-Pacific Region: Result from TAHOD. AIDS Res Treat. 2012;2012:375217. http://dx.doi.org/10.1155/2012/375217
Larson BA, Brennan A, McNamara L, Long L, Rosen S, Sanne I, et al . Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010;15(Supl.1):43-7. http://dx.doi.org/10.1111/j.1365-3156.2010.02511.x.
Namusobya J, Semitala FC, Amanyire G, Kabami J, Chamie G, Bogere J, et al . High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/µL under routine program conditions in Uganda. Clin Infect Dis. 2013;57:1343-50. http://dx.doi.org/10.1093/cid/cit490
Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al . Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51:135-9. http://dx.doi.org/10.1097/QAI.0b013e 3181a44ef2
Clouse K, Pettifor A, Maskew M, Bassett J, van Rie A, Gay C, et al . Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013;27:645-50. http://dx.doi.org/10.1097/QAD.0b013e32835c12f9
Maskew M, MacPhail P, Menezes C, Rubel D. Lost to follow up: Contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J. 2007;97:853-7.
Gill VC, Krentz HB. Patient perspectives on leaving, disengaging, and returning to HIV care. AIDS Patient Care STDS. 2015;29:400-7. http://dx.doi.org/10.1089/apc.2015.0001
Lebouché B, Yazdanpanah Y, Gérard Y, Sissoko D, Ajana F, Alcaraz I, et al . Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Med. 2006;7:140-5. http://dx.doi.org/10.1111/j.1468-1293.2006.00357.x
Hassan AS, Fielding KL, Thuo NM, Nabwera HM, Sanders EJ, Berkley JA. Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: A cohort study. Trop Med Int Health. 2012;17:82-93. http://dx.doi.org/10.1111/j.1365-3156.2011.02889.x
Arrivillaga M. Análisis de las barreras para la adherencia terapéutica en mujeres colombianas con VIH/sida: cuestión de derechos de salud. Salud Pública Mex. 2010;52:350-6.
Arrivillaga M, Ross M, Useche B, Alzate ML, Correa D. Social position, gender role, and treatment adherence Colombian women living with HIV/AIDS: Social determinants of health approach. Rev Panam Salud Pública. 2009;26:502-10. http://dx.doi.org/10.1590/S1020-49892009001200005
Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost or just not following up: Public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013;27:2271-9. http://dx.doi.org/10.1097/QAD.0b013e328362fdde
Rice BD, Delpech VC, Chadborn TR, Elford J. Loss to follow-up among adults attending human immunodeficiency virus services in England, Wales, and Northern Ireland. Sex Transm Dis. 2011;38:685-90. http://dx.doi.org/10.1097/OLQ.0b013e318214b92e.
Odafe S, Idoko O, Badru T, Aiyenigba B, Suzuki C, Khamofu H, et al . Patients´ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:17424. http://dx.doi.org/10.7448/IAS.15.2.17424.
Ndiaye B, Ould-Kaci K, Salleron J, Bataille P, Bonnevie F, Choisy P, et al . Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006. Antivir Ther. 2009;14:567-75.
Nacher M, El Guedj M, Vaz T, Nasser V, Randrianjohany A, Álvarez F, et al . Risk factors for follow-up interruption of HIV patients in French Guiana. Am J Trop Med Hyg. 2006;74:915-7.
Peltzer K, Ramlagan S, Khan MS, Gaede B. The social and clinical characteristics of patients on antiretroviral therapy who are ´lost to follow-up´ in KwaZulu-Natal, South Africa: A prospective study. SAHARA J. 2011;8:179-86. http://dx.doi.org/10.1080/17290376.2011.9725002
Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al . Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One. 2011;6:e18435. http://dx.doi.org/10.1371/journal.pone.0018435.
Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12:687-94. http://dx.doi.org/10.1111/j.1365-3156.2007.01830.x
Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr. 2007;44:30-7. http://dx.doi.org/10.1097/01.qai.0000248351.10383.b7
Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: Consequences for AIDS incidence. AIDS. 2002;16:1945-51.
Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Río C, Strathdee S, et al . Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19:423-31.
Lo W, MacGovern T, Bradford J. Association of ancillary services with primary care utilization and retention for patients with HIV/AIDS. AIDS Care. 2002;14(Supl.1):S45-57. http://dx.doi.org/10.1080/0954012022014992049984
Hoffmann M, MacCarthy S, Batson A, Crawford-Roberts A, Rasanathan J, Nunn A, et al . Barriers along the care cascade of HIV-infected men in a large urban center of Brazil. AIDS Care. 2015;20:1-6. http://dx.doi.org/10.1080/09540121.2015.1062462
Some similar items:
- Vanihamín Domínguez, Itzen Aguiñiga, Leticia Moreno, Beatriz Torres, Edelmiro Santiago-Osorio, Sodium caseinate increases the number of B lymphocytes in mouse , Biomedica: Vol. 37 No. 4 (2017)
- Luis A. Franco, Germán E. Matiz, Jairo Calle, Roberto Pinzón, Luis F. Ospina, Antiinflammatory activity of extracts and fractions obtained from Physalis peruviana L. calyces , Biomedica: Vol. 27 No. 1 (2007)
- Sandra Paola Ochoa, Carlos Andrés Ospina, Kelly Johana Colorado, Yenny Paola Montoya, Andrés Fernando Saldarriaga, Marisol Miranda, Natalia Muñoz, María Eugenia Gómez, Fanny Lucía Yepes, Javier Enrique Botero, Periodontal condition and tooth loss in diabetic patients , Biomedica: Vol. 32 No. 1 (2012)
- Luz E. Botero, Andrés E. Toro, Alber J. Patiño, Guillermo Salazar, Juan C. Rodríguez, Juan C. Suárez-Escudero, Gustavo A. Alarcón, Ana Corcimaru, Cristina Osorio, Joseph S. Y. Jeong, Oscar Alzate, Diabetes mellitus in patients with Alzheimer’s disease: clinical description and correlation with the APOE genotype in a sample population from the province of Antioquia, Colombia , Biomedica: Vol. 32 No. 2 (2012)
- Luis Ángel Villar, Rosa Margarita Gélvez, Jairo Antonio Rodríguez, Doris Salgado, Beatriz Parra, Lyda Osorio, Irene Bosch, Biomarkers for the prognosis of severe dengue , Biomedica: Vol. 33 (2013): Suplemento 1, Fiebres hemorrágicas
- Juan Carlos Miguel, Ariana Erazo, Fernanda Beduino, Juan Carlos Picena, María Isabel Luciano, Gustavo Pizzuti, María Cristina Tarrés, Silvana Montenegro, Stella Maris Martínez, Chronic bronchial dilatations in different colonies of laboratory rats , Biomedica: Vol. 22 No. 2 (2002)
- Silvana Marisa Montenegro, María Cristina Tarrés, Juan Carlos Picena, Stella Maris Martínez, Feeding behavior and glycemic profile in two lines of rats with genetic diabetes. , Biomedica: Vol. 25 No. 4 (2005)
- Fabián Jaimes, Gisela de la Rosa, Anticoagulation and sepsis: the opportunity for a new use of heparin?. , Biomedica: Vol. 26 No. 1 (2006)
- Argemiro Fragozo, María Fernanda Puerta, Juan Diego Misas, Comparative analysis of insulin glargine vs. insulin detemir: A cost-minimization study applicable to Colombia , Biomedica: Vol. 35 No. 2 (2015)
- Leticia Bequer, Tahiry Gómez, José Luis Molina, Daniel Artiles, Rosa Bermúdez, Sonia Clapés, Streptozotocin diabetogenic action in an experimental neonatal induction model , Biomedica: Vol. 36 No. 2 (2016)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
